A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients von Farmer, Isabel, Babiker, Samah, Okikiolu, Jumoke Stella, Steel, Matthew, Wanniarachchi, Chandima, Littlewood, Shona, Tan, Yishi, Imaeva, Kameta, Duran, Ana, Douvali, Evdoxia, Thanigaikumar, Murugaiyan, Gupta, Sunil, Yeghen, Tullie, Rashid, Sabia, Mir, Naheed, Sahu, Satyajit, Oram, Sarah

Volltext

Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience von Papoutselis, Menelaos, Douvali, Evdoxia, Papadopoulos, Vasileios, Spanoudakis, Emmanouil, Margaritis, Dimitrios, Tsatalas, Costas, Kotsianidis, Ioannis

Volltext

Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment von Douvali, Evdoxia, Papoutselis, Menelaos, Vassilakopoulos, Theodoros P, Papadopoulos, Vasileios, Spanoudakis, Emmanouil, Tsatalas, Costas, Kotsianidis, Ioannis

Volltext